Blood Advances | 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase.
Gupta V, Kennedy JA, Capo-Chichi J-M, Kim S, Hu Z-H, Alyea EP, Popat UR, Sobecks RM, Scott BL, Gerds AT, Salit RB, Deeg HJ, Nakamura R, Saber W
PubMed
PMID: 33170935
Abstract
Related Articles
CIBMTR Study #: CK15-03a